Dublin, Feb. 05, 2019 (GLOBE NEWSWIRE) -- The "Brain Tumor Therapeutics: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the current and future global market potential for brain tumor therapeutics. It provides a detailed analysis and information about conventional treatment options, ongoing market trends and the future direction of the market with respect to brain tumor therapy.
The development of combination therapies involving surgery, radiotherapy and chemotherapeutic agents, along with innumerable ongoing research and clinical trials for evolving targeted therapies and novel immunotherapeutic strategies are expected to offer promising alternatives to conventional treatments in the future. In addition, novel methods of drug delivery such as such as nano-particle mediated drug delivery, super selective intra-arterial cranial infusions and chemotherapeutic wafers help to further extend the lifespan of patients diagnosed with this disease and significantly improve the overall quality of survival.
Immune response-based strategies like monoclonal antibodies, brain cancer vaccines, and oncolytic viral therapies are in clinical trials and are expected to offer enormous potential for growth in this market. In coordination with conventional and adjunct therapies, immune-response based strategies will result in a sizable expansion of the brain tumor therapeutics market in the future.
Inclusions
- The report covers a detailed background of the disease state, along with epidemiological and demographic data, market segmentation by therapy (chemotherapy and targeted therapy), age group of patients (adult and pediatric brain tumors), end users (hospitals, cancer research institutes and medical universities) and a detailed regional market analysis including North America, Europe, Asia-Pacific and the rest of the world.
- The report provides information on newer treatment opportunities and cutting-edge research on therapeutics for brain tumors. It covers various types of treatment used in the field of neuro-oncology: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.
- A detailed analysis of agents used in the market for chemotherapy, immunotherapy and targeted therapy, as well as a pipeline analysis of newer molecules and therapeutics is covered in the report.
- A comprehensive analysis of market dynamics in the industry and current market trends are described in the report, along with the competitive landscape and discussion about key market players in the field of brain tumor therapeutics, where market strategies of these players are studied and described. The report includes a patent analysis of brain tumor therapeutics.
- The report concludes with company profiles of key players in the development and commercialization of brain tumor therapeutics.
- A separate chapter on emerging trends and breakthrough technologies in the field of neuro-oncology has been included in this report.
Market values are provided for 2017 as base year, 2018 and forecast through 2023. Estimated values are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation. The Report Includes:
- 20 data tables and 40 additional tables
- Comprehensive overview of the global market for brain tumor therapeutics within the pharmaceutical industry
- Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
- Impact analysis of major drivers and restraints, and regional dynamics of the global brain tumor therapeutics markets and current trends within the industry
- Company profiles of prominent players in the market, including Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis International AG
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
- Key Findings
Chapter 3 Disease Background and Overview
- Introduction
- What is Cancer?
- Cancer Drivers
- Cancer Staging
- Disease Background
- Brain Tumor Statistics
- Human Brain Function
- Causes of Tumor Development
- Mechanism of Tumorigenesis
- Types and Classification of Brain Tumors
- Diagnosis of Brain Tumors
- Magnetic Resonance Imaging (MRI)
- Magnetic Resonance Spectroscopy (MRS)
- Tissue Sampling/Biopsy/Surgical Removal of Tumor
- Computed Tomography (CT)
- Positron Emission Tomography (PET) or PET-CT Scan
- Cerebral Arteriogram
- Lumbar Puncture or Spinal Tap
- Myelogram
- Molecular Testing
- Neurological, Vision and Hearing Tests
- Neurocognitive Assessment
- Electroencephalography (EEG)
- Evoked Potentials
- Recurrence of Brain Tumors and Management
- Brain Tumor Metastases and Management
- Cognitive Challenges
- Pain Management
- Treatment Modalities
- Surgery
- Neurosurgery
- Emerging Treatments in Neurosurgery
- Radiotherapy
- New and Emerging Treatments in Neuro-radiotherapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
Chapter 4 Market Dynamics
- Introduction
- Market Drivers
- Increasing Global Incidence of Brain Cancer
- Early Cancer Detection
- Research Initiatives
- R&D Collaborations
- Increase in Oncology Spending
- Accelerated Approvals for Drugs Used in Rare Diseases
- Market Restraints
- Lack of Effective Treatment Options for Brain Tumors
- High Cost
- Low Screening
- Current Market Trends
- Immunotherapy
- Combination Therapy
- MRI-Guided Laser Surgery
- Palliative Therapy
- 3D Radiation Therapy
- Precision Medicine and Companion Diagnostics
- Polymer Wafer Implants
- Tumor Treating Fields (TTF)
Chapter 5 Market Breakdown by Therapy
- Introduction
- Chemotherapy
- Overview
- Principle of Chemotherapy
- BBB and Chemotherapy
- Chemotherapeutic Agents
- Side Effects of Chemotherapy
- New Developments
- Market Overview
- Market Size and Forecast
- Targeted Therapy
- Introduction
- Precision Medicine in Cancer
- Types and Methods of Targeted Therapy
- Drug Delivery Systems for Targeted Therapeutics
- FDA-Approved Targeted Therapeutics
- New Developments
- Market Overview
- Market Size and Forecast
- Immunotherapy
- Introduction
- Immunotherapeutic Agents
- New Developments
- Market Overview
Chapter 6 Market Breakdown by Patient Age
- Introduction
- Overview
- Treatment Options
- Market Overview
- Market Size and Forecast
Chapter 7 Market Breakdown by End User Chapter 8 Market Breakdown by Region
- Introduction
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 9 Emerging Technologies and Future Trends
- Introduction
- Cancer Vaccines
- Nanomedicine
- Stem Cell Therapy
- Photodynamic Therapy
- Focused Ultrasound Therapy
- Radiomics and Pathomics
- CRISPR
- Artificial Intelligence
- Advancements in Genomics and Personalized Medicine
Chapter 10 Clinical Research in Brain Tumor Therapeutics
- Introduction
- The Drug Development Process
- Drug Discovery
- Early Formulation Studies
- Pre-Clinical Safety Studies
- Clinical Trials
- Regulatory Review
- Post-Marketing Surveillance
- Research Initiatives
- Defeat GBM Research Collaborative
- Cancer Moonshot
- End Brain Cancer Initiative
- Brain Cancer Translational Research Initiative
- Pediatric Brain Tumor Initiative
- GLIOTRAIN
- GBM Agile
- Clinical Trials and Experimental Treatments
Chapter 11 Patent Review
- Introduction
- Significant Patents
Chapter 12 Competitive Landscape and Market Strategies
- Introduction
- Major Players and Market Share Analysis
- Market Strategies Employed, by Major Players
- Research and Development
- Patent Exclusivity
- Mergers and Acquisitions (M&A)
- New Developments
- Porter's Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat from New Entrants
- Threat from Substitutes
- Market Competition
Chapter 13 Regulatory and Reimbursement Landscape
- Introduction
- Drug Development Regulations
- U.S.
- Canada
- Mexico
- Europe
- Asia Pacific
- ROW
- Reimbursement Landscape
Chapter 14 Company Profiles
- Astra Zeneca Plc
- Bristol-Myers Squibb Co.
- Curtana Pharmaceuticals, Inc.
- Del Mar Pharmaceuticals, Inc.
- Eisai Co. Ltd.
- Emcure Pharma
- F. Hoffmann-La Roche Ltd.
- Fresenius Kabi Oncology Ltd.
- Immunocellular Therapeutics Ltd.
- Iteos Therapeutics
- Kazia Therapeutics Ltd.
- Merck & Co., Inc.
- Navinta Llc
- Nextsource Biotechnology Llc
- Northwest Biotherapeutics, Inc.
- Novartis International Ag
- Tocagen, Inc.
- United Therapeutics Corp.
For more information about this report visit https://www.researchandmarkets.com/research/s...tumor?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Brain Cancer Drugs
